Table 4 Treatment-related events occurring in at least 15% of patients, all grade 3 or 4 toxicities and immune-related adverse events.
From: Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
Toxicity description CTCAE v4.0 | Grade 1 or 2 | Grade 3 | Grade 4 | |
|---|---|---|---|---|
N (%) | N (%) | N (%) | ||
Gastrointestinal disorders | Abdominal pain or discomfort | 4 (22%) | – | – |
Constipation | 4 (22%) | – | – | |
Diarrhea | 3 (17%) | 1 (6%) | – | |
Nausea | 6 (33%) | – | – | |
Vomiting | 5 (28%) | – | – | |
Constitutional | Fatigue | 7 (39%) | – | – |
Fever | 6 (33%) | – | – | |
Weight loss | 4 (22%) | – | – | |
Anorexia | 6 (33%) | – | – | |
Hepatobiliary disorders infections | Hepatitis | – | 1 (6%) | – |
Alanine aminotransferase increaseda | 3 (17%) | 2 (11%) | – | |
Aspartate aminotransferase increaseda | 4 (22%) | 2 (11%) | – | |
Alkaline phosphatase increaseda | 2 (11%) | – | – | |
Amylase increased | – | 1 (6%) | – | |
Lipase increased | – | – | 1 (6%) | |
Aspiration pneumonia | – | 1 (6%) | – | |
Sepsis | – | 1 (6%) | – | |
Renal | Acute kidney injury | – | 1 (6%) | – |
Hypokalemia | – | 1 (6%) | – | |
Musculoskeletal | Back pain | 4 (22%) | – | – |
Nervous system | Encephalopathy | – | 1 (6%) | – |
Headache | 4 (22%) | – | – | |
Skin disorders | Pruritus | 4 (22%) | – | – |
Rash | 6 (33%) | – | – | |
Vascular disorders | Hypotension | – | 1 (6%) | – |
